# A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

> **NCT06425991** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Janssen Research & Development, LLC** · enrollment: 108 (actual)

## Conditions studied

- Relapsed or Refractory Multiple Myeloma

## Interventions

- **DRUG:** Teclistamab

## Key facts

- **NCT ID:** NCT06425991
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-06-07
- **Primary completion:** 2027-02-28
- **Final completion:** 2027-03-03
- **Target enrollment:** 108 (ACTUAL)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06425991

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06425991, "A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT06425991. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*